Background
Osteoporosis, a chronic, progressive disease of multifactorial etiology (see Etiology), is the most common metabolic bone disease in the United States. It has been most frequently recognized in elderly white women, although it does occur in both sexes, all races, and all age groups. Screening at-risk populations is essential (see Workup).
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility.[1] The disease often does not become clinically apparent until a fracture occurs (see the following image).
Osteoporosis. Lateral radiograph demonstrates multiple osteoporotic vertebral compression fractures. Kyphoplasty has been performed at one level. Osteoporosis represents an increasingly serious health and economic problem in the United States and around the world.[2] Many individuals, male and female, experience pain, disability, and diminished quality of life as a result of having this condition.
Despite the adverse effects of osteoporosis, it is a condition that is often overlooked and undertreated, in large part because it is so often clinically silent before manifesting in the form of fracture. For example, a Gallup survey performed by the National Osteoporosis Foundation revealed that 86% of all women aged 45-75 years had never discussed osteoporosis with their physicians, and more than 80% were unaware that osteoporosis is directly responsible for disabling hip fractures.[3] Failure to identify at-risk patients, to educate them, and to implement preventive measures may lead to tragic consequences.
Medical care includes calcium, vitamin D, and antiresorptive agents such as bisphosphonates, the selective estrogen receptor modulator (SERM) raloxifene, calcitonin, and denosumab. One anabolic agent, teriparatide (see Medication), is available as well. Surgical care includes vertebroplasty and kyphoplasty (see Treatment).
Osteoporosis is a preventable disease that can result in devastating physical, psychosocial, and economic consequences. Prevention and recognition of the secondary causes of osteoporosis are first-line measures to lessen the impact of this condition (see the images below).
Osteoporosis of the spine. Observe the considerable reduction in overall vertebral bone density and note the lateral wedge fracture of L2.
Osteoporosis of the spine. Note the lateral wedge fracture in L3 and the central burst fracture in L5. The patient had suffered a recent fall. WHO definition of osteoporosis
Bone mineral density (BMD) in a patient is related to peak bone mass and, subsequently, bone loss. Whereas the T-score is the patient’s bone density compared with the BMD of control subjects who are at their peak BMD, the Z-score reflects a bone density compared with that of patients matched for age and sex.[4, 5, 6, 7]
The World Health Organization’s (WHO) definitions of osteoporosis based on BMD measurements in white women are summarized in Table 1, below.[6, 7] For each standard deviation (SD) reduction in BMD, the relative fracture risk is increased 1.5-3 times.
The WHO definition applies to postmenopausal women and men aged 50 years or older. Although these definitions are necessary to establish the prevalence of osteoporosis, they should not be used as the sole determinant of treatment decisions. This diagnostic classification should not be applied to premenopausal women, men younger than 50 years, or children.
Table 1. WHO Definition of Osteoporosis Based on BMD Measurements by DXA (Open Table in a new window)
| Definition | Bone Mass Density Measurement | T-Score |
| Normal | BMD within 1 SD of the mean bone density for young adult women | T-score ≥ –1 |
| Low bone mass (osteopenia) | BMD 1–2.5 SD below the mean for young-adult women | T-score between –1 and –2.5 |
| Osteoporosis | BMD ≥2.5 SD below the normal mean for young-adult women | T-score ≤ –2.5 |
| Severe or “established” osteoporosis | BMD ≥2.5 SD below the normal mean for young-adult women in a patient who has already experienced ≥1 fractures | T-score ≤ –2.5 (with fragility fracture[s]) |
| Sources: (1) World Health Organization (WHO). WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed February 6, 2012.[8] (2) Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. Nov 1994;4(6):368-81.[7] (3) Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil. Jul-Aug 2007;9(4):337-56.[6] BMD = bone mass density; DXA = dual x-ray absorptiometry; SD = standard deviation; T-score = a measurement expressed in SD units from a given mean that is equal to a patient's BMD measured by DXA minus the value in a young healthy person, divided by the SD measurement in the population.[9] . | ||
Z-scores should be used in premenopausal women, men younger than 50 years, and children. Z-scores adjusted for ethnicity or race should be used, with Z-scores of –2.0 or lower defined as "below the expected range for age" and with Z-scores above –2.0 being defined as "within the expected range for age." The diagnosis of osteoporosis in these groups should not be based on densitometric criteria alone.
For more information, see Pediatric Osteoporosis, as well as Osteoporosis in Solid Organ Transplantation, Bone Markers in Osteoporosis, and Nonoperative Treatment of Osteoporotic Compression Fractures.
Pathophysiology
It is increasingly being recognized that multiple pathogenetic mechanisms interact in the development of the osteoporotic state. Understanding the pathogenesis of osteoporosis starts with knowing how bone formation and remodeling occur.
Normal bone formation and remodeling
Bone is continually remodeled throughout our lives in response to microtrauma. Bone remodeling occurs at discrete sites within the skeleton and proceeds in an orderly fashion, and bone resorption is always followed by bone formation, a phenomenon referred to as coupling.
Dense cortical bone and spongy trabecular or cancellous bone differ in their architecture but are similar in molecular composition. Both types of bone have an extracellular matrix with mineralized and nonmineralized components. The composition and architecture of the extracellular matrix is what imparts mechanical properties to bone. Bone strength is determined by collagenous proteins (tensile strength) and mineralized osteoid (compressive strength).[10] The greater the concentration of calcium, the greater the compressive strength. In adults, approximately 25% of trabecular bone is resorbed and replaced each year, compared with only 3% of cortical bone.
Osteoclasts, derived from mesenchymal cells, are responsible for bone resorption, whereas osteoblasts, from hematopoietic precursors, are responsible for bone formation (see the images below). The 2 types of cells are dependent on each other for production and linked in the process of bone remodeling. Osteoblasts not only secrete and mineralize osteoid but also appear to control the bone resorption carried out by osteoclasts. Osteocytes, which are terminally differentiated osteoblasts embedded in mineralized bone, direct the timing and location of bone remodeling. In osteoporosis, the coupling mechanism between osteoclasts and osteoblasts is thought to be unable to keep up with the constant microtrauma to trabecular bone. Osteoclasts require weeks to resorb bone, whereas osteoblasts need months to produce new bone. Therefore, any process that increases the rate of bone remodeling results in net bone loss over time.[11]
This image depicts bone remodeling with osteoclasts resorbing one side of a bony trabecula and osteoblasts depositing new bone on the other side.
Osteoclast, with bone below it. This image shows typical distinguishing characteristics of an osteoclast: a large cell with multiple nuclei and a "foamy" cytosol.
In this image, several osteoblasts display a prominent Golgi apparatus and are actively synthesizing osteoid. Two osteocytes can also be seen. Furthermore, in periods of rapid remodeling (eg, after menopause), bone is at an increased risk for fracture because the newly produced bone is less densely mineralized, the resorption sites are temporarily unfilled, and the isomerization and maturation of collagen are impaired.[12]
The receptor activator of nuclear factor-kappa B ligand (RANKL)/receptor activator of nuclear factor-kappa B (RANK)/osteoprotegerin (OPG) system is the final common pathway for bone resorption. Osteoblasts and activated T cells in the bone marrow produce the RANKL cytokine. RANKL binds to RANK expressed by osteoclasts and osteoclast precursors to promote osteoclast differentiation. Osteoprotegerin is a soluble decoy receptor that inhibits RANK-RANKL by binding and sequestering RANKL.
Bone mass peaks around the third decade of life and slowly decreases afterward. A failure to attain optimal bone strength by this point is one factor that contributes to osteoporosis, which explains why some young postmenopausal women have low bone mineral density (BMD) and why some others have osteoporosis. Therefore, nutrition and physical activity are important during growth and development. Nevertheless, hereditary factors play the principal role in determining an individual's peak bone strength. In fact, genetics account for up to 80% of the variance in peak bone mass between individuals.[13, 14]
Alterations in bone formation and resorption
The hallmark of osteoporosis is a reduction in skeletal mass caused by an imbalance between bone resorption and bone formation. Under physiologic conditions, bone formation and resorption are in a fair balance. A change in either—that is, increased bone resorption or decreased bone formation—may result in osteoporosis.
Osteoporosis can be caused both by a failure to build bone and reach peak bone mass as a young adult and by bone loss later in life. Accelerated bone loss can be affected by hormonal status, as occurs in perimenopausal women; can impact elderly men and women; and can be secondary to various disease states and medications.
Aging and loss of gonadal function are the 2 most important factors contributing to the development of osteoporosis. Studies have shown that bone loss in women accelerates rapidly in the first years after menopause. The lack of gonadal hormones is thought to up-regulate osteoclast progenitor cells. Estrogen deficiency leads to increased expression of RANKL by osteoblasts and decreased release of OPG; increased RANKL results in recruitment of higher numbers of preosteoclasts as well as increased activity, vigor, and lifespan of mature osteoclasts.
Estrogen deficiency
Estrogen deficiency not only accelerates bone loss in postmenopausal women but also plays a role in bone loss in men. Estrogen deficiency can lead to excessive bone resorption accompanied by inadequate bone formation. Osteoblasts, osteocytes, and osteoclasts all express estrogen receptors. In addition, estrogen affects bones indirectly through cytokines and local growth factors. The estrogen-replete state may enhance osteoclast apoptosis via increased production of transforming growth factor (TGF)–beta.
In the absence of estrogen, T cells promote osteoclast recruitment, differentiation, and prolonged survival via IL-1, IL-6, and tumor necrosis factor (TNF)–alpha. A murine study, in which either the mice's ovaries were removed or sham operations were performed, found that IL-6 and granulocyte-macrophage CFU levels were much higher in the ovariectomized mice.[15] This finding provided evidence that estrogen inhibits IL-6 secretion and that IL-6 contributes to the recruitment of osteoclasts from the monocyte cell line, thus contributing to osteoporosis.
IL-1 has also been shown to be involved in the production of osteoclasts. The production of IL-1 is increased in bone marrow mononuclear cells from ovariectomized rats. Administering IL-1 receptor antagonist to these animals prevents the late stages of bone loss induced by the loss of ovarian function, but it does not prevent the early stages of bone loss. The increase in the IL-1 in the bone marrow does not appear to be a triggered event but, rather, a result of removal of the inhibitory effect of sex steroids on IL-6 and other genes directly regulated by sex steroids.
T cells also inhibit osteoblast differentiation and activity and cause premature apoptosis of osteoblasts through cytokines such as IL-7. Finally, estrogen deficiency sensitizes bone to the effects of parathyroid hormone (PTH).
Aging
In contrast to postmenopausal bone loss, which is associated with excessive osteoclast activity, the bone loss that accompanies aging is associated with a progressive decline in the supply of osteoblasts in proportion to the demand. This demand is ultimately determined by the frequency with which new multicellular units are created and new cycles of remodeling are initiated.
After the third decade of life, bone resorption exceeds bone formation and leads to osteopenia and, in severe situations, osteoporosis. Women lose 30-40% of their cortical bone and 50% of their trabecular bone over their lifetime, as opposed to men, who lose 15-20% of their cortical bone and 25-30% of trabecular bone.
Calcium deficiency
Calcium, vitamin D, and PTH help maintain bone homeostasis. Insufficient dietary calcium or impaired intestinal absorption of calcium due to aging or disease can lead to secondary hyperparathyroidism. PTH is secreted in response to low serum calcium levels. It increases calcium resorption from bone, decreases renal calcium excretion, and increases renal production of 1,25-dihydroxyvitamin D (1,25[OH]2 D)—an active hormonal form of vitamin D that optimizes calcium and phosphorus absorption, inhibits PTH synthesis, and plays a minor role in bone resorption.
Vitamin D deficiency
Vitamin D deficiency can result in secondary hyperparathyroidism via decreased intestinal calcium absorption. Interestingly, the effects of PTH and 1,25[OH]2 D on bone are mediated via binding to osteoblasts and stimulating the RANKL/RANK pathway. Osteoclasts do not have receptors for PTH or 1,25[OH]2 D.[10]
Osteoporotic fractures
Osteoporotic fractures represent the clinical significance of these derangements in bone. They can result both from low-energy trauma, such as falls from a sitting or standing position, and from high-energy trauma, such as a pedestrian struck in a motor vehicle accident. Fragility fractures, which occur secondary to low-energy trauma, are characteristic of osteoporosis.
Fractures occur when bones fall under excess stress. Nearly all hip fractures are related to falls.[16] The frequency and direction of falls can influence the likelihood and severity of fractures. The risk of falling may be amplified by neuromuscular impairment due to vitamin D deficiency with secondary hyperparathyroidism or corticosteroids.
Vertebral bodies are composed primarily of cancellous bone with interconnected horizontal and vertical trabeculae. Osteoporosis not only reduces bone mass in vertebrae but also decreases interconnectivity in their internal scaffolding.[10] Therefore, minor loads can lead to vertebral compression fractures.
An understanding of the biomechanics of bone provides greater appreciation as to why bone may be susceptible to an increased risk of fracture. When vertical loads are placed on bone, such as tibial and femoral metaphyses and vertebral bodies, a substantial amount of bony strength is derived from the horizontal trabecular cross-bracing system. This system of horizontal cross-bracing trabeculae assists in supporting the vertical elements, thus limiting lateral bowing and fractures that may occur with vertical loading.
Disruption of such trabecular connections is known to occur preferentially in patients with osteoporosis, particularly in postmenopausal women, making females more at risk than males for vertebral compression fractures (see the images below).
Osteoporosis is defined as a loss of bone mass below the threshold of fracture. This slide (methylmethacrylate embedded and stained with Masson's trichrome) demonstrates the loss of connected trabecular bone.
The bone loss of osteoporosis can be severe enough to create separate bone "buttons" with no connection to the surrounding bone. This easily leads to insufficiency fractures. Rosen and Tenenhouse studied the unsupported trabeculae and their susceptibility to fracture within each vertebral body and found an extraordinarily high prevalence of trabecular fracture callus sites within vertebral bodies examined at autopsy, typically 200-450 healing or healed fractures per vertebral body.[17] These horizontal trabecular fractures are asymptomatic, and their accumulation reflects the impact of lost trabecular bone and greatly weakens the cancellous structure of the vertebral body.
The reason for preferential osteoclastic severance of horizontal trabeculae is unknown. Some authors have attributed this phenomenon to overaggressive osteoclastic resorption.
Osteoporosis versus osteomalacia
Osteoporosis may be confused with osteomalacia. The normal human skeleton is composed of a mineral component, calcium hydroxyapatite (60%), and organic material, mainly collagen (40%). In osteoporosis, the bones are porous and brittle, whereas in osteomalacia, the bones are soft. This difference in bone consistency is related to the mineral-to-organic material ratio. In osteoporosis, the mineral-to-collagen ratio is within the reference range, whereas in osteomalacia, the proportion of mineral composition is reduced relative to organic mineral content.
Additional factors and conditions
Endocrinologic conditions or medications that lead to bone loss (eg, glucocorticoids) can cause osteoporosis. Corticosteroids inhibit osteoblast function and enhance osteoblast apoptosis.[18] Polymorphisms of IL-1, IL-6 and TNF-alpha, as well as their receptors, have been found to influence bone mass.
Other factors implicated in the pathogenesis of osteoporosis include polymorphisms in the vitamin D receptor; alterations in insulin-like growth factor-1, bone morphogenic protein, prostaglandin E2, nitrous oxide, and leukotrienes; collagen abnormalities; and leptin-related adrenergic signaling.[11]
Epigenetics
Prenatal and postnatal factors contribute to adult bone mass. In one study, the health of the mother in pregnancy, the infant’s birth weight, and the child’s weight at age 1 year were predictive of adult bone mass in the seventh decade for men and women.[19] It is postulated that growth in the first year of life programs growth hormone that is maintained into the seventh decade.[20] Larger babies and rapid growth in the first year of life predicted increased bone mass in adults aged 65-75 years.
Etiology
Osteoporosis has been divided into several classifications according to etiology and localization in the skeleton. Osteoporosis is initially divided into localized and generalized categories, and these 2 main categories are further classified further into primary and secondary osteoporosis.
Postmenopausal osteoporosis (PMO) is primarily due to estrogen deficiency, senile osteoporosis is primarily due to an aging skeleton and calcium deficiency.
Primary osteoporosis
Patients are said to have primary osteoporosis when a secondary cause of osteoporosis cannot be identified, including juvenile and idiopathic osteoporosis. Idiopathic osteoporosis can be further subdivided into postmenopausal (type I) and age-associated or senile (type II) osteoporosis, as described in Table 2, below.
Table 2. Types of Primary Osteoporosis (Open Table in a new window)
| Type of Primary Osteoporosis | Characteristics |
| Juvenile osteoporosis |
|
| Idiopathic osteoporosis | |
|
|
|
|
Secondary osteoporosis
Secondary osteoporosis occurs when an underlying disease, deficiency, or drug causes osteoporosis (see Table 3, below). Up to one third of postmenopausal women, as well as many men and premenopausal women, have a coexisting cause of bone loss,[21, 22] of which renal hypercalciuria is one of the most important secondary causes of osteoporosis and treatable with thiazide diuretics.[23]
Table 3. Causes of Secondary Osteoporosis in Adults (Open Table in a new window)
| Cause | Examples |
| Genetic/congenital |
|
| Hypogonadal states |
|
| Endocrine disorders[24] |
|
| Deficiency states |
|
| Inflammatory diseases |
|
| Hematologic and neoplastic disorders |
|
| Medications |
|
| Miscellaneous |
|
| Sources: (1) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. Nov-Dec 2003;9(6):544-64.[21] (2) Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. Dec 2005;19(6):1021-37.[22] | |
Risk factors
Risk factors for osteoporosis, such as advanced age and reduced bone mineral density (BMD), have been established by virtue of their direct and strong relationship to the incidence of fractures; however, many other factors have been considered risk factors based on their relationship to BMD as a surrogate indicator of osteoporosis.
Risk factors for osteoporosis include the following[29, 30, 31] :
- Advanced age (≥50 years)
- Female sex
- White or Asian ethnicity
- Genetic factors, such as a family history of osteoporosis
- Thin build or small stature (eg, body weight less than 127 lb)
- Amenorrhea
- Late menarche
- Early menopause
- Postmenopausal state
- Physical inactivity or immobilization[32]
- Use of drugs: anticonvulsants, systemic steroids, thyroid supplements, heparin, chemotherapeutic agents, insulin
- Alcohol and tobacco use
- Androgen[33] or estrogen deficiency
- Calcium deficiency
- Dowager hump
A potentially useful mnemonic for osteoporotic risk factors is OSTEOPOROSIS, as follows:
- L O w calcium intake
- S eizure meds (anticonvulsants)
- T hin build
- E thanol intake
- Hyp O gonadism
- P revious fracture
- Thyr O id excess
- R ace (white, Asian)
- O ther relatives with osteoporosis
- S teroids
- I nactivity
- S moking
A study by Cummings et al evaluated 9516 white women aged 65 years for an average of 4.1 years and found an indirect relationship between the number of risk factors and bone density values.[34] The study also identified factors that did not increase the risk of fracture, including hair color, number of children breastfed, prior smoking history, or use of short-acting benzodiazepines. An interesting finding of this study was that dietary intake of calcium was not correlated with the risk of hip fracture; however, the authors of the study did agree with other experts that dietary calcium would only help if the patient was calcium deficient.
Epidemiology
According to the National Osteoporosis Foundation (NOF), 10 million Americans have osteoporosis. Another 34 million have low bone mass, which leaves them at increased risk for osteoporosis.[35] In the United States, 1.5 million osteoporotic fractures occur each year. Of these, 700,000 are spinal fractures; 300,000 are hip fractures; and 200,000 are wrist fractures.
Most studies assessing the prevalence and incidence of osteoporosis use the rate of fracture as a marker for the presence of this disorder, although BMD also relates to risk of disease and fracture. The risk of new vertebral fractures increases by a factor of 2-2.4 for each standard deviation (SD) decrease of BMD measurement. Women and men with metabolic disorders associated with secondary osteoporosis have a 2- to 3-fold higher risk of hip and vertebral fractures.
Globally, osteoporosis is by far the most common metabolic bone disease, and it is estimated to affect over 200 million people worldwide.[36] An estimated 75 million people in Europe, the United States, and Japan have osteoporosis.[37] Approximately 1 in 2 women and 1 in 5 men older than 50 years will eventually experience osteoporotic fractures.[35] By 2050, the worldwide incidence of hip fracture is projected to increase by 240% in women and 310% in men.[38]
Age demographics
Risk for osteoporosis increases with age as BMD declines. Senile osteoporosis is most common in persons aged 70 years or older. Secondary osteoporosis, however, can occur in persons of any age. Although bone loss in women begins slowly, it speeds up around the time of menopause, typically at about or after age 50 years. The frequency of postmenopausal osteoporosis is highest in women aged 50-70 years.
The number of osteoporotic fractures increases with age. Wrist fractures typically occur first, when individuals are aged approximately 50-59 years.
Vertebral fractures occur more often in the seventh decade of life. Jensen et al studied Danish women aged 70 years and found a 21% prevalence of vertebral fractures.[39] Melton et al reported that 27% of women in their study had evidence of vertebral fractures by age 65 years.[40]
Ninety percent of hip fractures occur in persons aged 50 years or older, occurring most often in the eighth decade of life.[41]
Sex demographics
Women are at a significantly higher risk for osteoporosis. According to the NOF, of the estimated 10 million Americans who have osteoporosis, 80% are women.[35] Men have a higher prevalence of secondary osteoporosis, with an estimated 45-60% of cases being a consequence of hypogonadism, alcoholism, or glucocorticoid excess.[27] Only 35-40% of osteoporosis diagnosed in men is considered primary in nature. Overall, osteoporosis has a female-to-male ratio of 4:1.[42]
Fifty percent of all women and 25% of all men older than 50 years experience one or more osteoporosis-related fracture in their lifetime. Eighty percent of hip fractures occur in women.[41] Women have a 2-fold increase in the number of fractures resulting from nontraumatic causes, as compared with men of the same age.
Racial demographics
Osteoporosis can occur in persons of all races and ethnicities. In general, however, whites (especially of northern European descent) and Asians are at increased risk. In particular, non-Hispanic white women and Asian women are at higher risk for osteoporosis. In the most recent government census, 178 million Chinese were over age 60 years in 2009, a number that the United Nations estimates may reach 437 million—one-third of the population—by 2050.[43] These numbers suggest that approximately 50% of all hip fractures will occur in Asia in the next century.
Table 4, below, summarizes some osteoporosis prevalence statistics among racial/ethnic groups. Note that this disease is underrecognized and undertreated in white and black women.[42] Relative to other racial/ethnic groups, the risk of developing osteoporosis is increasing fastest among Hispanic women.[42]
Table 4. Prevalence of Osteoporosis Among Racial and Ethnic Groups (Open Table in a new window)
| Race/Ethnicity | Sex (age ≥50 y) | % Estimated to have osteoporosis | % Estimated to have low bone mass |
| Non-Hispanic white; Asian | Women | 20 | 52 |
| Men | 7 | 35 | |
| Non-Hispanic black | Women | 5 | * |
| Men | 4 | 19 | |
| Hispanic | Women | 10 | 49 |
| Men | 3 | 23 | |
| Source: National Osteoporosis Foundation. Fast facts. Available at: http://www.nof.org/node/40. Accessed: February 16, 2012.[42] * Low bone density is present in an additional 35% of black women, increasing their risk of developing osteoporosis. | |||
Melton et al reported that the prevalence of hip fractures is higher in white populations, regardless of geographic location.[44] Another study indicated that, in the United States and South Africa, the incidence of hip fractures was lower in black persons than in age-matched white persons. Cauley et al found that the absolute fracture incidence across bone mineral density (BMD) distribution was 30-40% lower in black women than in white women. This lower fracture risk was independent of BMD and other risk factors.[45]
Prognosis
The prognosis for osteoporosis is good if bone loss is detected in the early phases and proper intervention is undertaken. Patients can increase BMD and decrease fracture risk with the appropriate anti-osteoporotic medication. In addition, patients can decrease their risk of falls by participating in a multifaceted approach that includes rehabilitation and environmental modifications. Worsening of medical status can be prevented by providing appropriate pain management and, if indicated, orthotic devices.
Effect of fractures on prognosis
Many individuals experience morbidity associated with the pain, disability, and diminished quality of life caused by osteoporosis-related fractures. According to a 2004 Surgeon General's report, osteoporosis and other bone diseases are responsible for about 1.5 million fractures per year. Osteoporosis-related fractures result in annual direct care expenditures of $12.2 billion to $17.9 billion.[46] In 2005, over 2 million osteoporosis-related fractures occurred in the United States.[47]
Osteoporosis is the leading cause of fractures in the elderly. Women aged 50 years have about a 50% lifetime fracture rate as a result of osteoporosis. Osteoporosis is associated with 80% of all the fractures in people aged 50 years or older.
If full recovery is not achieved, osteoporotic fractures may lead to chronic pain, disability, and, in some cases, death. This is particularly true of vertebral and hip fractures.
Vertebral fractures
Vertebral compression fractures (see the images below) are associated with increased morbidity and mortality rates. In addition, the impact of vertebral fractures increases as they increase in number. As posture worsens and kyphosis progresses, patients experience difficulty with balance, back pain, respiratory compromise, and an increased risk of pneumonia. Overall function declines, and patients may lose their ability to live independently.
Osteoporosis. Lateral radiograph demonstrates multiple osteoporotic vertebral compression fractures. Kyphoplasty has been performed at one level.
Osteoporosis. Lateral radiograph of the patient seen in the previous image following kyphoplasty performed at 3 additional levels. In one study, Cooper et al found that vertebral fractures increased the 5-year risk of mortality by 15%.[48] In a subsequent study, Kado et al[49] demonstrated that women with one or more fractures had a 1.23-fold increased age-adjusted mortality rate and that women with 5 or more vertebral fractures had a 2.3-fold increased age-adjusted mortality rate.
Furthermore, mortality rate was correlated with number of vertebral fractures, with 19 per 1000 woman-years in women with no fracture, versus 44 per 1000 woman-years in women with 5 or more fractures. Vertebral fractures were related to risk of subsequent cancer and pulmonary death, and severe kyphosis was further correlated with pulmonary deaths.
Only one third of people with radiographic vertebral fractures are diagnosed clinically.[50] Symptoms of vertebral fracture may include back pain, height loss, and disabling kyphosis. Compression deformities can lead to restrictive lung disease, abdominal pain, and early satiety.
Hip fractures
More than 250,000 hip fractures are attributed to osteoporosis each year.[34] Like vertebral fractures, they are associated with significantly increased morbidity and mortality rates in men and women. In the year following hip fracture, excess mortality rates can be as high as 20%.[48, 51] Men have higher mortality rates following hip fracture than do women.
Patients with hip fractures incur decreased independence and a diminished quality of life. Of all patients with hip fracture, approximately 20% require long-term nursing care.[35] Among women who sustain a hip fracture, 50% spend time in a nursing home while recovering. Approximately 50% of previously independent individuals become partially dependent, and one third become completely dependent.[52] Only one third of patients return to their prefracture level of function.[53]
Secondary complications of hip fractures include nosocomial infections and pulmonary thromboembolism.
Additional fractures
Patients who have sustained one osteoporotic fracture are at increased risk for developing additional osteoporotic fractures.[37] For example, the presence of at least one vertebral fracture results in a 5-fold increased risk of developing another vertebral fracture. One in 5 postmenopausal women with a new vertebral fracture incurs another vertebral fracture within one year.[54]
Patients with previous hip fracture have a 2-fold[55] to 10-fold increased risk of sustaining a second hip fracture. In addition, patients with ankle, knee, olecranon, and lumbar spine fractures have a 1.5-, 3.5-, 4.1-, and 4.8-fold increased risk of subsequent hip fracture, respectively.
WHO fracture-risk algorithm
The World Health Organization fracture-risk algorithm (FRAX) was developed to calculate the 10-year probability of a hip fracture and the 10-year probability of any major osteoporotic fracture (defined as clinical spine, hip, forearm, or humerus fracture) in a given patient. These calculations account for femoral neck bone mineral density (BMD) and other clinical risk factors, as follows[56] :
- Age
- Sex
- Personal history of fracture
- Low body mass index
- Use of oral glucocorticoid therapy
- Secondary osteoporosis (ie, coexistence of rheumatoid arthritis)
- Parental history of hip fracture
- Current smoking status
- Alcohol intake (3 or more drinks per day)
The National Osteoporosis Foundation (NOF) recommends osteoporosis treatment in patients with low bone mass in whom a US-adapted WHO 10-year probability of a hip fracture is 3% or more or in whom the risk for a major osteoporosis-related fracture is 20% or more.[35] Note that osteoporosis is, by definition, present in those with a fragility fracture, irrespective of their T-score.
Algorithms such as the FRAX algorithm are useful in identifying patients with low bone mass (T-scores in the osteopenic range) who are most likely to benefit from treatment. A study by Leslie et al demonstrated the effects of including a patient's 10-year fracture risk along with DXA results in Manitoba, Canada.[57] The authors found an overall reduction in dispensation of osteoporosis medications as more women were reclassified into lower fracture risk categories.
One study sought to determine if the femoral neck BMD score and FRAX score are associated with hip and nonspine fracture risk in older adults with type 2 diabetes mellitus (DM). Using data from 3 prospective observational studies, statistics from self-reported incidence of fractures in 9449 women and 7436 men in the United States were analyzed. The results found that participants with type 2 DM had a higher fracture risk and T-score than those without type 2 DM, concluding that the femoral neck BMD T-score and FRAX score were associated with higher hip and nonvertebral fracture risk in older adult patients with type 2 DM.[58]
Complications
Vertebral compression fractures often occur with minimal stress, such as coughing, lifting, or bending. The vertebrae of the middle and lower thoracic spine and upper lumbar spine are involved most frequently. In many patients, vertebral fracture can occur slowly and without symptoms.
Hip fractures are the most devastating and occur most commonly at the femoral neck and intertrochanteric regions (see the image below). Hip fractures are associated with falls. The likelihood of sustaining a hip fracture during a fall is related to the direction of the fall. Fractures are more likely to occur in falls to the side; less subcutaneous tissue is available to dissipate the impact. Secondary complications of hip fractures include nosocomial infections and pulmonary thromboembolism.
Stable intertrochanteric fracture of the femur. Fractures can cause further complications, including chronic pain from vertebral compression fractures and increased morbidity and mortality secondary to vertebral compression fractures and hip fractures. Patients with multiple fractures have significant pain, which leads to functional decline and a poor quality of life (QOL).[59] They are also at risk for the complications associated with immobility, including deep vein thrombosis (DVT) and pressure ulcers. Respiratory compromise can occur in patients with multiple vertebral fractures that result in severe kyphosis.
Patients with osteoporosis develop spinal deformities and a dowager's hump, and they may lose 1-2 inches of height by their seventh decade of life. These patients can lose their self-esteem and are at increased risk for depression.
Patient Education
Patient education is paramount in the treatment of osteoporosis. Many patients are unaware of the serious consequences of osteoporosis, including increased morbidity and mortality, and only become concerned when osteoporosis manifests in the form of fracture; accordingly, it is important to educate them regarding these consequences. Early prevention and treatment are essential in the appropriate management of osteoporosis.
The focus of patient education is on the prevention of osteoporosis. Prevention has 2 components, behavior modification and pharmacologic interventions. Appropriate preventive measures may include adequate calcium and vitamin D intake, exercise, cessation of smoking, and moderation of alcohol consumption.
Patients should be educated about the risk factors for osteoporosis, with a special emphasis on family history and the effects of menopause. Patients also need to be educated about the benefits of calcium and vitamin D supplements, as well as strategies to prevent falls in the elderly (see Primary Care–Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the US Preventive Services Task Force [USPSTF]).
All postmenopausal women older than 65 years should be offered bone densitometry, as well as some younger women and men. These patients should understand the benefits of bone density monitoring. Society at large also should be educated about the benefits of exercise with regard to osteoporosis.
For patient education information, see the Osteoporosis Center, Digestive Disorders Center, and Women's Health Center, as well as Osteoporosis, Anorexia Nervosa, Inflammatory Bowel Disease, and Menopause.
Ahmed SF, Elmantaser M. Secondary osteoporosis. Endocr Dev. 2009;16:170-90. [Medline].
[Best Evidence] Majumdar SR, Lier DA, Beaupre LA, Hanley DA, Maksymowych WP, Juby AG, et al. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med. Jan 12 2009;169(1):25-31. [Medline].
National Osteoporosis Foundation. Gallup survey: women's knowledge of osteoporosis. Am Fam Physician. 1991;44:1052.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. Mar 2008;42(3):467-75. [Medline].
Silverman SL. Selecting patients for osteoporosis therapy. Ann N Y Acad Sci. Nov 2007;1117:264-72. [Medline].
Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil. Jul-Aug 2007;9(4):337-56. [Medline].
Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. Nov 1994;4(6):368-81. [Medline].
World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report. Available at http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed February 6, 2012.
WebMD. Medical dictionary: T-score. Available at http://dictionary.webmd.com/terms/t-score. Accessed February 6, 2012.
Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. Oct 2003;12 Suppl 2:S90-6. [Medline].
Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. Dec 2005;115(12):3318-25. [Medline].
Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. May 25 2006;354(21):2250-61. [Medline].
Mora S, Gilsanz V. Establishment of peak bone mass. Endocrinol Metab Clin North Am. Mar 2003;32(1):39-63. [Medline].
Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. Dec 2011;64(12):1042-50. [Medline].
Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. Jul 3 1992;257(5066):88-91. [Medline].
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. May 18 2002;359(9319):1761-7. [Medline].
Rosen CJ, Tenenhouse A. Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Postgrad Med. Oct 1998;104(4):101-2, 107-10.
Ringe JD, Farahmand P. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol. Apr 2007;26(4):474-84. [Medline].
Dennison EM, Syddall HE, Sayer AA, Gilbody HJ, Cooper C. Birth weight and weight at 1 year are independent determinants of bone mass in the seventh decade: the Hertfordshire cohort study. Pediatr Res. Apr 2005;57(4):582-6. [Medline].
Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C. Programming of growth hormone secretion and bone mineral density in elderly men: a hypothesis. J Clin Endocrinol Metab. Jan 1998;83(1):135-9. [Medline].
[Guideline] American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. Nov-Dec 2003;9(6):544-64. [Medline].
Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. Dec 2005;19(6):1021-37. [Medline].
Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med. Apr 20 1999;130(8):658-60. [Medline].
Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol. Aug 1 2009;27(22):3605-10. [Medline].
Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-81. [Medline].
di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol. Jul 2004;31(7):1305-9. [Medline].
Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag. Apr 2009;5(2):305-10. [Medline]. [Full Text].
van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. Oct 2002;13(10):777-87. [Medline].
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. [Medline].
Lyles KW, Schenck AP, Colón-Emeric CS. Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int. Aug 2008;19(8):1225-33. [Medline]. [Full Text].
Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE. Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. Sep 2008;19(9):1277-82. [Medline].
Sinaki M. Exercise and osteoporosis. Arch Phys Med Rehabil. Mar 1989;70(3):220-9. [Medline].
Yaturu S, DjeDjos S, Alferos G, Deprisco C. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Prostate Cancer Prostatic Dis. 2006;9(1):35-8. [Medline].
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. Mar 23 1995;332(12):767-73. [Medline].
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Available at http://www.nof.org/professionals/clinical-guidelines. Accessed January 13, 2011.
Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. Nov 1992;2(6):285-9. [Medline].
Who are candidates for prevention and treatment for osteoporosis?. Osteoporos Int. 1997;7(1):1-6. [Medline].
Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407-13. [Medline].
Jensen GF, Christiansen C, Boesen J, Hegedüs V, Transbøl I. Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res. Jun 1982;75-81. [Medline].
Melton LJ 3rd, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. May 1989;129(5):1000-11. [Medline].
Smith R, Wordsworth P. Osteoporosis. In: Clinical and Biochemical Disorders of the Skeleton. 2005:123.
National Osteoporosis Foundation. Fast facts. Available at http://www.nof.org/node/40. Accessed February 16, 2012.
Balfour F. China's "Demographic Tsunami." Bloomberg Businessweek. January 5, 2012. Available at http://www.businessweek.com/magazine/chinas-demographic-tsunami-01052012.html. Accessed February 16, 2012.
Melton LJ 3rd, Sampson JM, Morrey BF, Ilstrup DM. Epidemiologic features of pelvic fractures. Clin Orthop Relat Res. Mar-Apr 1981;43-7. [Medline].
Cauley JA, Lui LY, Ensrud KE, Zmuda JM, Stone KL, Hochberg MC, et al. Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA. May 4 2005;293(17):2102-8. [Medline].
Bone Health and Osteoporosis: A Report of the Surgeon General. Washington, DC: Department of Health and Human Services; 2004. [Full Text].
Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. Mar 2007;22(3):465-75. [Medline].
Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. May 1 1993;137(9):1001-5. [Medline].
Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. Jun 14 1999;159(11):1215-20. [Medline].
Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. Feb 1992;7(2):221-7. [Medline].
Vestergaard P, Rejnmark L, Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int. Dec 2007;18(12):1583-93. [Medline].
Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int. Sep 2002;13(9):731-7. [Medline].
Michel JP, Hoffmeyer P, Klopfenstein C, et al. Prognosis of functional recovery 1 year after hip fracture: typical patient profiles through cluster analysis. J Gerontol A Biol Sci Med Sci. Sep 2000;55(9):M508-15. [Medline].
Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. Jan 17 2001;285(3):320-3. [Medline].
Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. Apr 2000;15(4):721-39. [Medline].
The World Health Organization Fracture Risk Assessment Tool. Available at http://www.shef.ac.uk/FRAX/. Accessed May 5, 2008.
Leslie WD, Morin S, Lix LM. Before-and-After Study of Fracture Risk Reporting and Osteoporosis Treatment Initiation. Ann Intern Med. Nov 2 2010;153(9):580-6.
Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. Jun 1 2011;305(21):2184-92. [Medline].
Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. Jun 1993;36(6):750-6. [Medline].
Schnatz PF, Marakovits KA, Dubois M, O'Sullivan DM. Osteoporosis screening and treatment guidelines: are they being followed?. Menopause. Oct 2011;18(10):1072-8. [Medline].
Chon KS, Sartoris DJ, Brown SA, Clopton P. Alcoholism-associated spinal and femoral bone loss in abstinent male alcoholics, as measured by dual X-ray absorptiometry. Skeletal Radiol. 1992;21(7):431-6. [Medline].
Geusens P, Dumitrescu B, van Geel T, van Helden S, Vanhoof J, Dinant GJ. Impact of systematic implementation of a clinical case finding strategy on diagnosis and therapy of postmenopausal osteoporosis. J Bone Miner Res. Jun 2008;23(6):812-8. [Medline].
U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. Jan 17 2011;[Medline].
Zhu K, Devine A, Lewis JR, Dhaliwal SS, Prince RL. "'Timed up and go' test and bone mineral density measurement for fracture prediction. Arch Intern Med. Oct 10 2011;171(18):1655-61. [Medline].
Lynn SG, Sinaki M, Westerlind KC. Balance characteristics of persons with osteoporosis. Arch Phys Med Rehabil. Mar 1997;78(3):273-7. [Medline].
Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. Dec 6 2011;155(11):751-61. [Medline].
[Guideline] Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Sep 16 2008;149(6):404-15. [Medline].
Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. Feb 2007;21(1):109-22. [Medline].
Guglielmi G, Muscarella S, Bazzocchi A. Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics. Sep-Oct 2011;31(5):1343-64. [Medline].
The International Society for Clinical Densitometry. 2007 ISCD Official Positions Brochure. Available at http://www.iscd.org/Visitors/positions/OfficialPositionsText.cfm. Accessed May 5, 2008.
Paunier L. Effect of magnesium on phosphorus and calcium metabolism. Monatsschr Kinderheilkd. Sep 1992;140(9 Suppl 1):S17-20. [Medline].
Lee WY, Oh KW, Rhee EJ, Jung CH, Kim SW, Yun EJ, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res. May 2006;37(4):511-6. [Medline].
Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. Oct 2002;87(10):4431-7. [Medline].
Liu JM, Zhao HY, Ning G, Chen Y, Zhang LZ, Sun LH, et al. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab. 2008;26(2):159-64. [Medline].
Resnick D, Kransdorf M. Osteoporosis. In: Bone and Joint Imaging. Third Edition. 2005:551.
Gosfield E 3rd, Bonner FJ Jr. Evaluating bone mineral density in osteoporosis. Am J Phys Med Rehabil. May-Jun 2000;79(3):283-91. [Medline].
Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. Dec 6 2011;155(11):751-61. [Medline]. [Full Text].
Lin JT, Lane JM. Bisphosphonates. J Am Acad Orthop Surg. Jan-Feb 2003;11(1):1-4. [Medline].
Kastner M, Straus SE. Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med. Dec 2008;23(12):2095-105. [Medline]. [Full Text].
Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother. Nov 2011;12(16):2533-52. [Medline].
Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. Rev Endocr Metab Disord. Jun 2006;7(1-2):101-12. [Medline].
Mulder JE, Kolatkar NS, LeBoff MS. Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab. Dec 2006;2(12):670-80. [Medline].
Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. Nov-Dec 2010;16 Suppl 3:1-37. [Medline]. [Full Text].
Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. Jun 13 2011;171(11):998-1004. [Medline].
[Best Evidence] Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. May 3 2007;356(18):1809-22. [Medline].
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. Nov 2011;59(11):2084-90. [Medline].
US Food and Drug Administration. FDA drug safety communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available at http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed September 1, 2011.
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. Mar 2005;90(3):1294-301. [Medline].
Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30(9):755-63. [Medline].
Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. Feb 23 2011;305(8):783-9. [Medline].
Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep. Mar 2009;7(1):12-7. [Medline].
[Best Evidence] Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, et al. Effect of Raloxifene on all-cause mortality. Am J Med. May 2010;123(5):469.e1-7. [Medline].
Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. Oct 2002;87(10):4528-35. [Medline].
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. Oct 2001;16(10):1846-53. [Medline].
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. May 10 2001;344(19):1434-41. [Medline].
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. Dec 2004;15(12):992-7. [Medline].
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. Sep 25 2003;349(13):1216-26. [Medline].
Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. Feb 2006;21(2):283-91. [Medline].
Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. Nov 2005;20(11):1905-11. [Medline].
[Best Evidence] Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am. Jun 2009;91(6):1329-38. [Medline].
Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. Sep 7 2011;93(17):1583-7. [Medline].
Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. Feb 15 2006;12(4):1221-8. [Medline].
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. Feb 23 2006;354(8):821-31. [Medline].
[Best Evidence] Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. Aug 20 2009;361(8):756-65. [Medline].
[Best Evidence] Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. Aug 20 2009;361(8):745-55. [Medline].
Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9 Suppl 1:S7. [Medline]. [Full Text].
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. Jul 17 2002;288(3):321-33. [Medline].
Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. J Bone Miner Res. Nov 2005;20(11):1901-4. [Medline].
Burlet N, Reginster JY. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. Clin Orthop Relat Res. Feb 2006;443:55-60. [Medline].
Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA. Feb 23 2011;305(8):800-7. [Medline].
[Best Evidence] Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. Mar 23 2009;169(6):551-61. [Medline].
Warensjö E, Byberg L, Melhus H, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ. May 24 2011;342:d1473. [Medline]. [Full Text].
Bruni V, Dei M, Filicetti MF, Balzi D, Pasqua A. Predictors of bone loss in young women with restrictive eating disorders. Pediatr Endocrinol Rev. Jan 2006;3 Suppl 1:219-21. [Medline].
Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. Apr 28 2004;291(16):1999-2006. [Medline].
[Best Evidence] Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. Aug 25 2007;370(9588):657-66. [Medline].
[Best Evidence] DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. Jan 12 2010;340:b5463. [Medline].
[Best Evidence] Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. Jul 29 2010;341:c3691. [Medline]. [Full Text].
Sinaki M. Postmenopausal spinal osteoporosis: physical therapy and rehabilitation principles. Mayo Clin Proc. Nov 1982;57(11):699-703. [Medline].
Tinetti ME, Speechley M. Prevention of falls among the elderly. N Engl J Med. Apr 20 1989;320(16):1055-9. [Medline].
Sinaki M, Mikkelsen BA. Postmenopausal spinal osteoporosis: flexion versus extension exercises. Arch Phys Med Rehabil. Oct 1984;65(10):593-6. [Medline].
Sinaki M, Itoi E, Wahner HW, Wollan P, Gelzcer R, Mullan BP, et al. Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone. Jun 2002;30(6):836-41. [Medline].
Sinaki M, Itoi E, Rogers JW, Bergstralh EJ, Wahner HW. Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil. Sep-Oct 1996;75(5):370-4. [Medline].
Chien MY, Wu YT, Hsu AT, Yang RS, Lai JS. Efficacy of a 24-week aerobic exercise program for osteopenic postmenopausal women. Calcif Tissue Int. Dec 2000;67(6):443-8. [Medline].
Snow CM, Shaw JM, Winters KM, Witzke KA. Long-term exercise using weighted vests prevents hip bone loss in postmenopausal women. J Gerontol A Biol Sci Med Sci. Sep 2000;55(9):M489-91. [Medline].
Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. Jul 6 2011;CD000333. [Medline].
Iwamoto J, Takeda T, Ichimura S. Effect of exercise training and detraining on bone mineral density in postmenopausal women with osteoporosis. J Orthop Sci. 2001;6(2):128-32. [Medline].
Kerschan-Shindl K, Uher E, Kainberger F, Kaider A, Ghanem AH, Preisinger E. Long-term home exercise program: effect in women at high risk of fracture. Arch Phys Med Rehabil. Mar 2000;81(3):319-23. [Medline].
Robertson MC, Devlin N, Gardner MM, Campbell AJ. Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised controlled trial. BMJ. Mar 24 2001;322(7288):697-701. [Medline]. [Full Text].
Walker M, Klentrou P, Chow R, Plyley M. Longitudinal evaluation of supervised versus unsupervised exercise programs for the treatment of osteoporosis. Eur J Appl Physiol. Nov 2000;83(4 -5):349-55. [Medline].
Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques. J Am Geriatr Soc. May 1996;44(5):489-97. [Medline].
Carter ND, Khan KM, Petit MA, Heinonen A, Waterman C, Donaldson MG, et al. Results of a 10 week community based strength and balance training programme to reduce fall risk factors: a randomised controlled trial in 65-75 year old women with osteoporosis. Br J Sports Med. Oct 2001;35(5):348-51. [Medline]. [Full Text].
Riggs BL, Melton LJ 3rd. The prevention and treatment of osteoporosis. N Engl J Med. Aug 27 1992;327(9):620-7. [Medline].
Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J. Feb 29 2008;49(1):119-28. [Medline]. [Full Text].
Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. Feb 19 1998;338(8):485-92. [Medline].
Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). Nov 2010;62(11):1515-26.
Schwab P, Klein RF. Nonpharmacological approaches to improve bone health and reduce osteoporosis. Curr Opin Rheumatol. Mar 2008;20(2):213-7. [Medline].
Lin JT, Lane JM. Nonmedical management of osteoporosis. Curr Opin Rheumatol. Jul 2002;14(4):441-6. [Medline].
Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. Jan 19 2012;366(3):225-33. [Medline]. [Full Text].
Kirshblum SC. Rehabilitation Medicine: Principles and Practice. In: DeLisa JA, Gans BM. Spinal and upper extremity orthotics. 3rd. Philadelphia, Pa: Lippincott-Raven; 1998:635-50.
Stillo JV. Low back orthoses. Phys Med Rehab Clin North Am. 1992;3:57-94.
NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA. Dec 28 1994;272(24):1942-8. [Medline].
Hulley SB, Grady D. The WHI estrogen-alone trial--do things look any better?. JAMA. Apr 14 2004;291(14):1769-71. [Medline].
Aloia JF, Vaswani A, Yeh JK, Flaster E. Risk for osteoporosis in black women. Calcif Tissue Int. Dec 1996;59(6):415-23. [Medline].
Boonen S, Orwoll E, Magaziner J, et al. Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture. J Am Geriatr Soc. Nov 2011;59(11):2084-2090. [Medline].
Canalis E. New treatments in osteoporosis. Bone. Sep 2001;29(3):296.
Cohen A, Dempster DW, Recker RR, Stein EM, Lappe JM, Zhou H, et al. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. Oct 2011;96(10):3095-105. [Medline]. [Full Text].
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. Aug 11 2005;353(6):566-75. [Medline].
Curtis JR, Carbone L, Cheng H, Hayes B, Laster A, Matthews R, et al. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res. Jul 2008;23(7):1061-7. [Medline]. [Full Text].
Jensen ME, Evans AJ, Mathis JM, Kallmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol. Nov-Dec 1997;18(10):1897-904. [Medline].
Lau EM, Cooper C. The epidemiology of osteoporosis. The oriental perspective in a world context. Clin Orthop Relat Res. Feb 1996;65-74. [Medline].
Lauderdale DS, Jacobsen SJ, Furner SE, Levy PS, Brody JA, Goldberg J. Hip fracture incidence among elderly Hispanics. Am J Public Health. Aug 1998;88(8):1245-7. [Medline]. [Full Text].
Ledlie JT, Renfro M. Balloon kyphoplasty: one-year outcomes in vertebral body height restoration, chronic pain, and activity levels. J Neurosurg. Jan 2003;98(1 Suppl):36-42. [Medline].
- Table 1. WHO Definition of Osteoporosis Based on BMD Measurements by DXA
- Table 2. Types of Primary Osteoporosis
- Table 3. Causes of Secondary Osteoporosis in Adults
- Table 4. Prevalence of Osteoporosis Among Racial and Ethnic Groups
- Table 5. Comparison of Densitometry Techniques and Cost-Effectiveness
- Table 6. Baseline Studies for Baseline Conditions in Osteoporosis
- Table 7. Tests for Secondary Causes of Osteoporosis
| Definition | Bone Mass Density Measurement | T-Score |
| Normal | BMD within 1 SD of the mean bone density for young adult women | T-score ≥ –1 |
| Low bone mass (osteopenia) | BMD 1–2.5 SD below the mean for young-adult women | T-score between –1 and –2.5 |
| Osteoporosis | BMD ≥2.5 SD below the normal mean for young-adult women | T-score ≤ –2.5 |
| Severe or “established” osteoporosis | BMD ≥2.5 SD below the normal mean for young-adult women in a patient who has already experienced ≥1 fractures | T-score ≤ –2.5 (with fragility fracture[s]) |
| Sources: (1) World Health Organization (WHO). WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed February 6, 2012.[8] (2) Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. Nov 1994;4(6):368-81.[7] (3) Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil. Jul-Aug 2007;9(4):337-56.[6] BMD = bone mass density; DXA = dual x-ray absorptiometry; SD = standard deviation; T-score = a measurement expressed in SD units from a given mean that is equal to a patient's BMD measured by DXA minus the value in a young healthy person, divided by the SD measurement in the population.[9] . | ||
| Type of Primary Osteoporosis | Characteristics |
| Juvenile osteoporosis |
|
| Idiopathic osteoporosis | |
|
|
|
|
| Cause | Examples |
| Genetic/congenital |
|
| Hypogonadal states |
|
| Endocrine disorders[24] |
|
| Deficiency states |
|
| Inflammatory diseases |
|
| Hematologic and neoplastic disorders |
|
| Medications |
|
| Miscellaneous |
|
| Sources: (1) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. Nov-Dec 2003;9(6):544-64.[21] (2) Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. Dec 2005;19(6):1021-37.[22] | |
| Race/Ethnicity | Sex (age ≥50 y) | % Estimated to have osteoporosis | % Estimated to have low bone mass |
| Non-Hispanic white; Asian | Women | 20 | 52 |
| Men | 7 | 35 | |
| Non-Hispanic black | Women | 5 | * |
| Men | 4 | 19 | |
| Hispanic | Women | 10 | 49 |
| Men | 3 | 23 | |
| Source: National Osteoporosis Foundation. Fast facts. Available at: http://www.nof.org/node/40. Accessed: February 16, 2012.[42] * Low bone density is present in an additional 35% of black women, increasing their risk of developing osteoporosis. | |||
| Single-photon absorptiometry | Dual-photon absorptiometry | Dual-energy x-ray absorptiometry | Quantitative computed tomography | |
| Time | 5-15 min | 20-30 min | 5-10 min | 10-30 min |
| Cost | $50-150 | $150-300 | $100-200 | $150-300 |
| Sites scanned | Radius, forearm, calcaneus | Spine, hip (anteroposterior) | Spine (lateral), hip, radius | Spine (lateral), hip, radius |
| Source: Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. Dec 6 2011;155(11):751-61.[68] | ||||
| Baseline test | Disorder |
| Complete blood count (CBC) | CBC results may reveal anemia, as in sickle cell disease (patients with anemia, particularly those older than 60 years, should also be evaluated for multiple myeloma), and may raise the suspicion for alcohol abuse (in conjunction with results from serum chemistry tests and liver function tests) |
| Serum chemistry levels | Calcium levels can reflect underlying disease states (eg, severe hypercalcemia may reflect underlying malignancy or hyperparathyroidism; hypocalcemia can contribute to osteoporosis) levels of serum calcium, phosphate, and alkaline phosphatase are usually normal in persons with primary osteoporosis, although alkaline phosphatase levels may be elevated for several months after a fracture levels of serum calcium, phosphate, alkaline phosphatase, and 25(OH) vitamin D may be obtained to assess osteomalacia Creatinine levels may decrease with increasing parathyroid hormone (PTH) levels or may be elevated in patients with multiple myeloma Creatinine levels are also used to estimate creatinine clearance, which may indicate reduced renal function in elderly patients Magnesium is very important in calcium homeostasis[71] ; decreased levels of magnesium may affect calcium absorption and metabolism |
| Serum iron and ferritin levels | These tests are helpful when malabsorption or hemochromatosis are suspected |
| Liver function tests | Increased levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin, and alkaline phosphatase may indicate alcohol abuse |
| Thyroid-stimulating hormone (TSH) level | Thyroid dysfunction has been associated with osteoporosis and should therefore be ruled out[72] |
| 25-Hydroxyvitamin D level | This test assesses for vitamin D insufficiency; inadequate vitamin D levels can predispose persons to osteoporosis |
| Tests for Secondary Causes of Osteoporosis | Disorder |
| 24-Hour urine calcium level | This study assesses for hypercalciuria to help rule out benign familial hypocalciuric hypercalcemia (FHH), in which urinary calcium levels are low |
| Parathyroid hormone (PTH) level | An intact PTH result is essential in ruling out hyperparathyroidism; an elevated PTH level may be present in benign FHH |
| Thyrotropin level (if on thyroid replacement) | Experts are divided on whether to include thyrotropin testing, regardless of a history of thyroid disease or replacement; however, one study showed reduced femoral neck bone mineral density (BMD) in women with subclinical hypothyroidism and hyperthyroidism[72] |
| Testosterone and gonadotropin levels in younger men with low bone densities | These tests may help evaluate a sex hormone deficiency as a secondary cause of osteoporosis |
| Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels | Some practitioners include ESR and CRP values in the workup, although their utility in this setting has not been proven in an evidence-based manner |
| Urinary free cortisol level and tests for adrenal hypersecretion | These tests are used to exclude Cushing syndrome, which, although uncommon, can lead to rapidly progressive osteoporosis when the condition is present; a urine free cortisol value or overnight dexamethasone suppression test should be ordered in suspected cases |
| Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) | These are used to identify multiple myeloma |
| Antigliadin and antiendomysial antibodies | These tests can help identify celiac disease |
| Serum tryptase and urine N-methylhistamine | These tests help identify mastocytosis and are used to exclude the presence of multiple myeloma; serum tryptase may be performed to rule out plasma cell dyscrasias |
| Bone marrow biopsy | This study is obtained when a hematologic disorder is suspected |

